IBDEI2EE ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40685,1,3,0)
 ;;=3^Irritant Contact Dermatitis,Unspec
 ;;^UTILITY(U,$J,358.3,40685,1,4,0)
 ;;=4^L24.9
 ;;^UTILITY(U,$J,358.3,40685,2)
 ;;=^5009136
 ;;^UTILITY(U,$J,358.3,40686,0)
 ;;=L25.9^^159^1993^115
 ;;^UTILITY(U,$J,358.3,40686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40686,1,3,0)
 ;;=3^Contact Dermatitis,Unspec
 ;;^UTILITY(U,$J,358.3,40686,1,4,0)
 ;;=4^L25.9
 ;;^UTILITY(U,$J,358.3,40686,2)
 ;;=^5133647
 ;;^UTILITY(U,$J,358.3,40687,0)
 ;;=L26.^^159^1993^148
 ;;^UTILITY(U,$J,358.3,40687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40687,1,3,0)
 ;;=3^Exfoliative Dermatitis
 ;;^UTILITY(U,$J,358.3,40687,1,4,0)
 ;;=4^L26.
 ;;^UTILITY(U,$J,358.3,40687,2)
 ;;=^263886
 ;;^UTILITY(U,$J,358.3,40688,0)
 ;;=L27.0^^159^1993^265
 ;;^UTILITY(U,$J,358.3,40688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40688,1,3,0)
 ;;=3^Skin Eruption d/t Drugs/Meds,Generalized
 ;;^UTILITY(U,$J,358.3,40688,1,4,0)
 ;;=4^L27.0
 ;;^UTILITY(U,$J,358.3,40688,2)
 ;;=^5009144
 ;;^UTILITY(U,$J,358.3,40689,0)
 ;;=L27.1^^159^1993^266
 ;;^UTILITY(U,$J,358.3,40689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40689,1,3,0)
 ;;=3^Skin Eruption d/t Drugs/Meds,Localized
 ;;^UTILITY(U,$J,358.3,40689,1,4,0)
 ;;=4^L27.1
 ;;^UTILITY(U,$J,358.3,40689,2)
 ;;=^5009145
 ;;^UTILITY(U,$J,358.3,40690,0)
 ;;=L29.0^^159^1993^250
 ;;^UTILITY(U,$J,358.3,40690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40690,1,3,0)
 ;;=3^Pruritus Ani
 ;;^UTILITY(U,$J,358.3,40690,1,4,0)
 ;;=4^L29.0
 ;;^UTILITY(U,$J,358.3,40690,2)
 ;;=^100061
 ;;^UTILITY(U,$J,358.3,40691,0)
 ;;=L29.9^^159^1993^251
 ;;^UTILITY(U,$J,358.3,40691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40691,1,3,0)
 ;;=3^Pruritus,Unspec
 ;;^UTILITY(U,$J,358.3,40691,1,4,0)
 ;;=4^L29.9
 ;;^UTILITY(U,$J,358.3,40691,2)
 ;;=^5009153
 ;;^UTILITY(U,$J,358.3,40692,0)
 ;;=L30.0^^159^1993^232
 ;;^UTILITY(U,$J,358.3,40692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40692,1,3,0)
 ;;=3^Nummular Dermatitis
 ;;^UTILITY(U,$J,358.3,40692,1,4,0)
 ;;=4^L30.0
 ;;^UTILITY(U,$J,358.3,40692,2)
 ;;=^186823
 ;;^UTILITY(U,$J,358.3,40693,0)
 ;;=L30.1^^159^1993^140
 ;;^UTILITY(U,$J,358.3,40693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40693,1,3,0)
 ;;=3^Dyshidrosis
 ;;^UTILITY(U,$J,358.3,40693,1,4,0)
 ;;=4^L30.1
 ;;^UTILITY(U,$J,358.3,40693,2)
 ;;=^5009154
 ;;^UTILITY(U,$J,358.3,40694,0)
 ;;=L30.2^^159^1993^132
 ;;^UTILITY(U,$J,358.3,40694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40694,1,3,0)
 ;;=3^Cutaneous Autosensitization
 ;;^UTILITY(U,$J,358.3,40694,1,4,0)
 ;;=4^L30.2
 ;;^UTILITY(U,$J,358.3,40694,2)
 ;;=^5009155
 ;;^UTILITY(U,$J,358.3,40695,0)
 ;;=L30.4^^159^1993^144
 ;;^UTILITY(U,$J,358.3,40695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40695,1,3,0)
 ;;=3^Erythema Intertrigo
 ;;^UTILITY(U,$J,358.3,40695,1,4,0)
 ;;=4^L30.4
 ;;^UTILITY(U,$J,358.3,40695,2)
 ;;=^5009157
 ;;^UTILITY(U,$J,358.3,40696,0)
 ;;=L30.8^^159^1993^135
 ;;^UTILITY(U,$J,358.3,40696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40696,1,3,0)
 ;;=3^Dermatitis NEC
 ;;^UTILITY(U,$J,358.3,40696,1,4,0)
 ;;=4^L30.8
 ;;^UTILITY(U,$J,358.3,40696,2)
 ;;=^5009158
 ;;^UTILITY(U,$J,358.3,40697,0)
 ;;=L30.9^^159^1993^136
 ;;^UTILITY(U,$J,358.3,40697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40697,1,3,0)
 ;;=3^Dermatitis,Unspec
 ;;^UTILITY(U,$J,358.3,40697,1,4,0)
 ;;=4^L30.9
 ;;^UTILITY(U,$J,358.3,40697,2)
 ;;=^5009159
 ;;^UTILITY(U,$J,358.3,40698,0)
 ;;=L40.0^^159^1993^253
 ;;^UTILITY(U,$J,358.3,40698,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40698,1,3,0)
 ;;=3^Psoriasis Vulgaris
